35results about How to "No hygroscopicity" patented technology

The invention discloses a low-moisture-absorption colloidal bismuth pectin capsule and a preparation technology thereof. In a preparation of the low-moisture-absorption colloidal bismuth pectin capsule, acrylic resin IV is taken as a coating material and light calcium carbonate is taken as an anti-sticking agent to coat colloidal bismuth pectin to obtain a coated pellet, and the obtained coated pellet is used to fill a capsule shell. The low-moisture-absorption colloidal bismuth pectin capsule and the preparation technology have the advantages that the problems that the colloidal bismuth pectin preparation is prone to absorbing moisture and clustering and not easy to disperse uniformly are solved, therapeutic efficacy of the colloidal bismuth pectin preparation is improved, less auxiliary materials are used, the preparation technology is simple, and the low-moisture-absorption colloidal bismuth pectin capsule is easy to produce industrially in large scale.

The present invention discloses a non-hygroscopicity protocatechuic acid berberine monohydrate having a crystal form, and belongs to the technical field of drug crystallization. According to the present invention, berberine hydrochloride, protocatechuic acid and sodium hydroxide are dissolved in an ethanol aqueous solution according to a certain ratio to form the protocatechuic acid berberine monohydrate crystal; the preparation method has characteristics of simpleness, easy performing, low cost, and high crystal yield; and the prepared protocatechuic acid berberine monohydrate crystal does not have the hygroscopicity, has the moderate solubility in water, can be rapidly dissolved, and can be used in cardiovascular diseases and anti-cancer.

The invention discloses a colloidal bismuth pectin capsule with low hygroscopicity and a preparation process thereof. The preparation uses acrylic resin IV as a coating material and light calcium carbonate as an anti-sticking agent to coat the colloidal bismuth pectin. The obtained Coated pellets are filled with capsule shells, which greatly improves the problem of easy moisture absorption and difficult dispersion of colloidal pectin bismuth preparations in the storage process, and improves the curative effect of the drug; at the same time, there are fewer types of excipients used, and the preparation process is simple and easy for industrialization Big production.

The invention belongs to the technical field of traditional Chinese medicine, and in particular relates to application of a lung tonifying and blood circulation promoting capsule for treating or preventing pulmonary injury. The traditional Chinese medicine composition selects medicinal materials with appropriate compatibility, conforms to research theories of traditional Chinese medicine and modern medicine, and has good drug effects and low toxic side effects. The traditional Chinese medicine composition is mainly prepared from astragalus root, red peony root and fructus psoraleae.

The invention relates to the technical field of synthesis of raw material medicines, and particularly discloses a preparation method of azelastine hydrochloride. The method comprises the following steps: condensing benzoyl hydrazine and 1-methylhexahydroazepine-4-one serving as raw materials, reducing with sodium borohydride, and reacting to obtain a compound 1; preparing a solid intermediate compound 2 from the compound 1 and organic binary weak acid; hydrolyzing the compound 2, and cyclizing with a compound 3 to form a compound 4; and salifying the compound 4 by hydrochloric acid, and separating water by toluene to obtain a compound 5, namely azelastine hydrochloride. The intermediate compound 2 prepared by the invention is a solid, the stability of the intermediate compound 2 is greatly improved compared with that of hydrochloride obtained in other literatures, the intermediate compound 2 is free of hygroscopicity, the purity can reach 99% or above, the quality risk of subsequent bulk drugs can be greatly reduced, and the process production operation space is larger; and the obtained azelastine hydrochloride does not contain water and meets related quality standards, the yield is increased to 80% or above compared with other literatures, and the purity can reach 99% or above.

The invention belongs to the technical field of pharmaceutical preparations, and relates to thyroid tablets produced by direct whole-powder tabletting and a preparation process of the thyroid tabletsproduced by the direct whole-powder tabletting, in particular to synergetic application of calcium hydrogen phosphate-assisted optimization of powder properties of thyroid raw materials and freeze-drying assisted grinding technology. More than 98% of the particle sizes of thyroid mixed ground materials prepared by the invention are smaller than 250 microns, and the thyroid mixed ground materials are difficultly reaggregated, and uniformly mixed with other auxiliary materials; RSD of the T3 and T4 contents in thyroid powder is not greater than 4%; the angle of repose of the mixed powder is smaller than 35 degrees, so that requirements of powder direct tabletting are met; the content uniformity (A+2.2S) of T3 and T4 in the thyroid tablets is not greater than 20, each tablet is disintegratedwithin 15min, and the disintegration time limit difference is small (RSD is not greater than 5%). The thyroid tablets produced by the direct whole-powder tabletting and the preparation process of thethyroid tablets produced by the direct whole-powder tabletting disclosed by the invention effectively solve the problems that the thyroid raw materials are not easily ground, and not uniformly mixed with the auxiliary materials and the like, optimize the grinding effect of the thyroid raw materials, improve the powder properties of the thyroid raw materials, and greatly enhance the content uniformity of T3 and T4 in the thyroid tablets.

The purpose of the invention is to provide a pyrroloquinoline quinone disodium salt crystal which is simple and suitable for large-scale production and a preparation method thereof, wherein the preparation method of the pyrroloquinoline quinone disodium salt crystal comprises the following steps: the pH of an aqueous solution containing a pyrroloquinoline quinone disodium salt or an alkali metal salt thereof is adjusted to 7.5-8.5, then the acid is added to adjust the pH to 3.0-4.0, the pyrroloquinoline quinone disodium salt crystal is obtained by desalting, crystallizing and drying. The preparation method has the advantages of simple and easy to control, and the obtained pyrroloquinoline quinone disodium salt crystal is almost free of moisture absorption.

The invention belongs to the technical field of pharmaceutical preparations, and relates to a thyroid tablet produced by full powder direct compression and a preparation process thereof, in particular to a synergistic application of calcium hydrogen phosphate assisted optimization of thyroid raw material powder properties and freeze-drying assisted pulverization technology. The particle size of the mixed pulverized thyroid material prepared by the present invention is more than 98% below 250 μm, it is not easy to re-aggregate, and it is evenly mixed with other auxiliary materials; T in thyroid powder 3 , T 4 The RSD of content≤4%; the angle of repose of mixed powder is less than 35°, meeting the requirement of powder direct compression; T in thyroid tablets 3 and T 4 The content uniformity of A+2.2S≤20, each tablet disintegrates within 15min, and the disintegration time limit difference is small (RSD≤5%). The present invention effectively solves the problems that thyroid raw materials are not easy to be crushed and unevenly mixed with auxiliary materials, etc., optimizes the pulverization effect of thyroid raw materials, improves the powder properties of thyroid raw materials, and greatly improves the T of thyroid tablets. 3 , T 4 content uniformity.

The present invention discloses a non-hygroscopicity protocatechuic acid berberine monohydrate having a crystal form, and belongs to the technical field of drug crystallization. According to the present invention, berberine hydrochloride, protocatechuic acid and sodium hydroxide are dissolved in an ethanol aqueous solution according to a certain ratio to form the protocatechuic acid berberine monohydrate crystal; the preparation method has characteristics of simpleness, easy performing, low cost, and high crystal yield; and the prepared protocatechuic acid berberine monohydrate crystal does not have the hygroscopicity, has the moderate solubility in water, can be rapidly dissolved, and can be used in cardiovascular diseases and anti-cancer.

The invention relates to an apixaban crystal form and a preparation method thereof, belonging to the field of medicine and chemical industry, in particular to an apixaban nicotinic acid monohydrate eutectic with anticoagulant activity and a preparation method thereof. It is disclosed that the obtained crystals are analyzed by X-ray powder diffraction spectrum, and the 2θ values ​​of the characteristic absorption peaks are located at 5.7±0.2゜, 6.0±0.2゜, 11.5±0.2゜, 13.3±0.2゜, 15.4±0.2゜, 15.8±0.2゜, 17.5±0.2゜, 17.7±0.2゜, 20.0±0.2゜, 22.1±0.2゜, 23.4±0.2゜. The preparation method has the advantages of cheap and easy-to-obtain reagents, environmental friendliness, simple preparation method, mild crystallization conditions and easy crystal separation. The apixaban nicotinic acid monohydrate cocrystal of the invention can be used for treating thromboembolic diseases.

The invention discloses a new crystal form of sofosbuvir and a preparation method thereof. The powder X-ray diffraction of the new crystal form of sofosbuvir of the present invention has characteristic peaks at 2θ: 8.4±0.2°, 9.1±0.2°, 16.9±0.2°, 19.7±0.2°, 25.5±0.2°. The new sofosbuvir crystal form of the present invention has stable quality, stable crystal form, no hygroscopicity, and good fluidity. The preparation method is simple and suitable for industrialization, and is more suitable for storage and use as a raw material drug, and provides a method for the preparation of sofosbuvir medicine. new way.

The invention relates to a crystal form of warnemuline hydrochloride hydrate, a preparation method thereof and a pharmaceutical composition containing the crystal form. Specifically, the present invention relates to the crystalline form of warnimulin hydrochloride hydrate, the characteristic peaks 2θ of the crystalline form in the X-ray powder diffraction spectrum are at 9.2±0.2°, 9.5±0.2°, 10.3±0.2°, 11.8±0.2 °, 12.3±0.2°, 12.8±0.2°, 15.1±0.2°, 17.5±0.2°, 18.2±0.2° display. The warnemulin hydrochloride hydrate crystal form has a large bulk density, no hygroscopicity and good stability. The present invention also provides a method for preparing the above-mentioned warnemuline hydrochloride hydrate crystal form and a pharmaceutical composition containing the crystal form, which can be used in the preparation of various preparations, such as soluble powder, oral liquid, sustained release Granules, injections and other dosage forms have broad prospects for clinical use.

The present invention relates to a new 2-(alpha-hydroxyamyl) benzoate and its preparation method, and medicine composition using said compound as active component, and also relates to its application for curing cardio-cerebral ischemia and cardio-cerebral arterial infarction.

The invention discloses a drug co-crystal of dihydromyricetin-berberine hydrochloride, which belongs to the technical field of drug crystallization. The present invention combines dihydromyricetin and berberine hydrochloride through intermolecular hydrogen bonding to form the dihydromyricetin-berberine hydrochloride drug eutectic. The preparation method of the invention is simple and easy, and the cost is low. The prepared dihydromyricetin-berberine hydrochloride drug eutectic structure is clear, without hygroscopicity, and the dissolution rate of dihydromyricetin and berberine hydrochloride in water is similar, and can be dissolved simultaneously, showing a synergistically enhanced effect on specific tumor cells. inhibition.

The invention relates to glucosamine sulfate compound salt and a preparation method thereof. The X-ray diffraction of the compound salt shows that the compound salt has a strongest peak at the position of 27.080 degrees. The preparation method comprises the following steps: 1, enabling chitin and a basic carbonate solution to have a deacetylation reaction under the condition of microwave heating, and drying to obtain glucosamine; 2, preparing the obtained glucosamine into a glucosamine solution, adding an excessive acid sulfate solution into the glucosamine solution for neutralizing the glucosamine solution, and enabling the glucosamine solution to be sulfated; removing the generated ammonia by using chlorine; adding activated carbon for carrying out a decolorizing reaction, and filtering the reaction product while the product is hot; 3, adding chlorine-containing metal salt into the solution obtained in the step 2, heating for carrying out an ion exchange reaction, and then carrying out a reflux reaction; 4, adding alcohol as a precipitator into the solution obtained after the reactions of the step 3 are finished, filtering to obtain precipitate, and carrying out freeze drying on the precipitate to obtain glucosamine sulfate compound salt concentrate. The preparation method provided by the invention is simple in production technology, low in cost and high in product purity, enables the quality of the product to reach the pharmacopeia standards, and can be used for large-scale production.

The invention relates to a compound polydatin, in particular to a crystal form of 3,4',5-trihydroxy-stilbene-3-beta-D-glucoside (polydatin) and a method for preparing the same, which belong to the field of medicinal and health products. On a differential scanning calorimetry spectrogram, the crystal form of the polydatin displays that a single sharp endothermic peak occurs at a temperature of 2252.0 DEG C, and one to two dehydration endothermic peaks occur at a temperature of between 50 and 100 DEG C. The crystal form of the polydatin has the advantages that: the novel crystal form of the polydatin contains 0.5-3 H2O crystallization water, is stable, and is difficultly converted into other crystal forms. The process for preparing the crystal form adopts water as a crystallization solvent, and has the advantages of simple process, easy control, stable obtained crystal form, good repeatability, and no problems of environmental pollution and residual solvents.

The invention relates to a crystal form of a spirocyclic dihydroisoquinoline carboxamide derivative and a preparation method thereof. Specifically, the present invention relates to the crystal form A of the compound represented by formula (I), which has good stability and can be better used in clinical treatment.

The invention belongs to the technical field of traditional Chinese medicine, and in particular relates to application of a lung tonifying and blood circulation promoting capsule for treating or preventing pulmonary injury. The traditional Chinese medicine composition selects medicinal materials with appropriate compatibility, conforms to research theories of traditional Chinese medicine and modern medicine, and has good drug effects and low toxic side effects. The traditional Chinese medicine composition is mainly prepared from astragalus root, red peony root and fructus psoraleae.